February 11, 2021
Features
41
2
Almost a year since the start of the pandemic, it’s clear a new medical vision is taking shape—one focused on serving patients now, solving procedural issues later.
February 11, 2021
Executive Profile
41
2
Melissa Thompson, Alcon’s head of global corporate social responsibility, discusses her career commitment to CSR and how COVID-19 has impacted the organization’s efforts to improve access to eye care around the globe.
February 11, 2021
Features
41
2
Pharma manufacturers may need to upgrade their coupon programs to accommodate for the emergence of copay accumulators and related benefit mechanisms.
February 11, 2021
Features
41
2
A look at the results of recent surveys revealing the impact of the COVID-triggered digital switchover on sales rep interactions and medical conferences.
February 11, 2021
Finance
41
2
Dueling paths leave market fortunes uncertain.
February 11, 2021
Global Report
41
2
Can private sector serve public interests in battling rare diseases?
February 11, 2021
Technology
41
2
With the UK maintaining a world-leading position in key areas of technology, 2021 could be a banner year for its life sciences.
February 11, 2021
Back Page
41
2
COVID-19 creates a unique chance to refocus STEM strategies.
February 11, 2021
Leadership
41
2
Creating stronger relationships can set off a chain of success.
February 11, 2021
Issue PDF
41
2
Click the title above for a link to open the Pharmaceutical Executive February 2021 issue in an interactive PDF format.
February 11, 2021
Features
41
2
Panelists in a recent roundtable share ideas on transforming company culture, fostering greater patient diversity, and acting on pharma’s fast-evolving social mandate.
February 11, 2021
From the Editor
41
2
Not to be outdone by the showbiz industry, Pharm Exec's own awards season is fast approaching.
February 11, 2021
Features
41
2
Telemedicine is definitely here to stay, but recent study may offer clues on its sustaining power.
January 07, 2021
Washington Report
41
2
Applications put on hold as agency limits alternative oversight methods.